TY - JOUR
T1 - Symptom Monitoring in Glioma Patients
T2 - Development of the Edmonton Symptom Assessment System Glioma Module
AU - Ijzerman-Korevaar, Margriet
AU - Snijders, Tom J.
AU - Teunissen, Saskia C.C.M.
AU - De Graeff, Alexander
AU - De Vos, Filip Y.F.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Background and Purpose: Symptoms in glioma patients are distinctly different from symptoms in patients with other types of cancer and have a high impact on quality of life. In this study, a stepwise approach of developing a glioma module for assessment of symptoms, based on a Dutch adapted and validated version of the Edmonton Symptom Assessment System, is described. Methods: Three phases of instrument development were conducted: A systematic literature review and a focus group interview with experts were performed (phase I) to generate relevant symptoms and construct a preliminary module (phase II). In phase III, the preliminary module was evaluated (n = 25) and pretested (n = 45) in glioma patients representing all phases of the disease. Results: Our glioma module contains 11 generic and 6 neurologic symptoms. Patients completed the glioma module in a median of 5 minutes, and 56% of the patients required some assistance to complete the instrument. Conclusion: The glioma module has initial validity and will benefit from prospective validation in a larger cohort of patients with glioma.
AB - Background and Purpose: Symptoms in glioma patients are distinctly different from symptoms in patients with other types of cancer and have a high impact on quality of life. In this study, a stepwise approach of developing a glioma module for assessment of symptoms, based on a Dutch adapted and validated version of the Edmonton Symptom Assessment System, is described. Methods: Three phases of instrument development were conducted: A systematic literature review and a focus group interview with experts were performed (phase I) to generate relevant symptoms and construct a preliminary module (phase II). In phase III, the preliminary module was evaluated (n = 25) and pretested (n = 45) in glioma patients representing all phases of the disease. Results: Our glioma module contains 11 generic and 6 neurologic symptoms. Patients completed the glioma module in a median of 5 minutes, and 56% of the patients required some assistance to complete the instrument. Conclusion: The glioma module has initial validity and will benefit from prospective validation in a larger cohort of patients with glioma.
KW - ESAS
KW - glioma
KW - PROM
KW - symptom diary
KW - symptom management
UR - http://www.scopus.com/inward/record.url?scp=85056424607&partnerID=8YFLogxK
U2 - 10.1097/JNN.0000000000000400
DO - 10.1097/JNN.0000000000000400
M3 - Article
C2 - 30407970
AN - SCOPUS:85056424607
SN - 0888-0395
VL - 50
SP - 381
EP - 387
JO - Journal of Neuroscience Nursing
JF - Journal of Neuroscience Nursing
IS - 6
ER -